



NRG-BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

[Click here to Listen](#)

Episode Description: The NRG Oncology Podcast co-hosts discuss triple-negative breast cancer in light of the recently presented results at the 2025 ASCO Annual Meeting. We interview Dr. Vicente Valero, the NRG-BR003 PI, and Dr. Julie Gralow, the Chief Medical Officer of ASCO about these findings and current research in breast cancer.



All episodes of The NRG Oncology Podcast can be found on Spotify, Apple Music, YouTube, & Amazon or you can stream them directly from our website at

www.NRGOncology.org/Podcast